Xi-Yuan Zhang

Xi-Yuan Zhang

Auto-generated profile, based on publicly available information

Xi-Yuan Zhang

Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Annals of Medicine
Verified
Journal Article
Open access
CZChuanlong Zhang
Chuanlong Zhang
MGMeng-Qi Gao
Meng-Qi Gao
XJXiao-Chen Jiang
Xiao-Chen Jiang
XPXue Pan
Xue Pan
XZXi-Yuan Zhang
Xi-Yuan Zhang
BPBo Pang
Bo Pang
Inflammatory markers have a wide range of predictive values in the prognosis of non-small lung cancer (NSCLC). Poor nutritional status usually means a poor prognosis in patients with NSCLC, which is widely recognized by oncologists and nutritionists. Serum albumin has a certain value in evaluating the prognosis of patients. Several inflammatory albumin-related markers have been proposed, but they have not been widely used in predicting the prognosis of NSCLC in clinical practice. We aim to systematically review the published clinical evidence of albumin-related inflammatory markers in predicting the prognosis of NSCLC and to describe their progress and value. The results showed that the markers included in the review could be prognostic indicators in patients with NSCLC. However, we found that the cut-off value of albumin-related inflammatory markers with quantitative nature was very chaotic and needed to be defined by recognized standards. We summarized and compared the advantages and disadvantages of these markers, but a prospective cohort study with long-term follow-up after adjustment for important confounders is still necessary. Whether the results and conclusions could be directly applied in clinical practice needs to be identified and evaluated. There is an urgent need to classify and standardize the albumin-related inflammatory markers that play an important role in the prognosis of NSCLC, which is the key to ensuring the transformation from clinical study to clinical application.